Dr. Reddy’s launches epilepsy drug in the US market1 min read . Updated: 26 Jun 2013, 07:08 PM IST
The firm launched lamotrigine extended-release tablets following approval by US Food and Drug Administration on 25 June
Drug maker Dr. Reddy’s Laboratories Ltd said on Wednesday it launched lamotrigine extended-release tablets in the US market following approval by the Food and Drug Administration on 25 June.
Lamotrigine is a generic version of GlaxoSmithKline Plc.’s lamictal XR used in the treatment of epilepsy.
According to US-based healthcare information service provider IMS Health, the lamictal XR brand and its generic had combined US sales of around $300.5 million for the 12 months ended April.
Dr. Reddy’s lamotrigine tablets will be available in 25mg, 50mg, 100mg, 200mg, and 300mg dosages.
Shares of Dr. Reddy’s dropped 0.32% to ₹ 2,093.15 on BSE, while the benchmark Sensex fell 0.41% to 18,552.12 points on Wednesday.